Human methylome studies SRP158409 Track Settings
 
H3K36me2 recruits DNMT3A and shapes intergenic DNA methylation landscapes [C3H embryo-derived mesenchymal progenitor, C57BL/6 x 129S4/SvJae F1 embryo-derived ESCs, Patient-derived head and neck squamous cell carcinoma cell line]

Track collection: Human methylome studies

+  All tracks in this collection (463)

Maximum display mode:       Reset to defaults   
Select views (Help):
CpG methylation ▾       PMD       AMR       HMR       CpG reads ▾      
Select subtracks by views and experiment:
 All views CpG methylation  PMD  AMR  HMR  CpG reads 
experiment
SRX4579183 
SRX4579184 
SRX4579185 
SRX4579186 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 Configure
 SRX4579183  CpG methylation  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579183 (CpG methylation)   Schema 
hide
 SRX4579183  PMD  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579183 (PMD)   Schema 
hide
 SRX4579183  AMR  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579183 (AMR)   Schema 
hide
 SRX4579184  HMR  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579184 (HMR)   Schema 
hide
 Configure
 SRX4579183  CpG reads  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579183 (CpG reads)   Schema 
hide
 Configure
 SRX4579184  CpG methylation  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579184 (CpG methylation)   Schema 
hide
 SRX4579184  PMD  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579184 (PMD)   Schema 
hide
 SRX4579184  AMR  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579184 (AMR)   Schema 
hide
 Configure
 SRX4579184  CpG reads  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579184 (CpG reads)   Schema 
hide
 Configure
 SRX4579185  CpG methylation  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579185 (CpG methylation)   Schema 
hide
 SRX4579185  PMD  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579185 (PMD)   Schema 
hide
 SRX4579185  AMR  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579185 (AMR)   Schema 
hide
 Configure
 SRX4579185  CpG reads  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579185 (CpG reads)   Schema 
hide
 Configure
 SRX4579186  CpG methylation  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579186 (CpG methylation)   Schema 
hide
 SRX4579186  PMD  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579186 (PMD)   Schema 
hide
 SRX4579186  AMR  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579186 (AMR)   Schema 
hide
 Configure
 SRX4579186  CpG reads  Patient-derived head and neck squamous cell carcinoma cell line / SRX4579186 (CpG reads)   Schema 
    

Study title: H3K36me2 recruits DNMT3A and shapes intergenic DNA methylation landscapes
SRA: SRP158409
GEO: GSE118785
Pubmed: 31485078

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Details
SRX4579183 Patient-derived head and neck squamous cell carcinoma cell line 0.663 25.7 138463 4076.0 2367 940.4 3060 286053.8 0.996 title: GSM3347566 WGBS_Cal27, Homo sapiens, Bisulfite-Seq; {"source_name": "Cal 27 cells", "cell_line": "Cal27", "cell_type": "Patient-derived head and neck squamous cell carcinoma cell line", "genotype": "NSD1 wild-type"}
SRX4579184 Patient-derived head and neck squamous cell carcinoma cell line 0.832 29.9 80401 1832.4 1287 891.7 1973 101468.7 0.994 title: GSM3347567 WGBS_Fadu, Homo sapiens, Bisulfite-Seq; {"source_name": "Fadu cells", "cell_line": "Fadu", "cell_type": "Patient-derived head and neck squamous cell carcinoma cell line", "genotype": "NSD1 wild-type"}
SRX4579185 Patient-derived head and neck squamous cell carcinoma cell line 0.538 27.9 93780 6404.8 2195 928.6 1569 888722.9 0.996 title: GSM3347568 WGBS_SCC_4, Homo sapiens, Bisulfite-Seq; {"source_name": "SCC-4 cells", "cell_line": "SCC-4", "cell_type": "Patient-derived head and neck squamous cell carcinoma cell line", "genotype": "NSD1 mutant"}
SRX4579186 Patient-derived head and neck squamous cell carcinoma cell line 0.492 29.1 115734 7628.4 3809 957.8 2362 761337.2 0.996 title: GSM3347569 WGBS_SKN_3, Homo sapiens, Bisulfite-Seq; {"source_name": "SKN-3 cells", "cell_line": "SKN-3", "cell_type": "Patient-derived head and neck squamous cell carcinoma cell line", "genotype": "NSD1 mutant"}

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.